Ogilvie G K, Powers B E, Mallinckrodt C H, Withrow S J
Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins 80523, USA.
J Vet Intern Med. 1996 Nov-Dec;10(6):379-84. doi: 10.1111/j.1939-1676.1996.tb02085.x.
Forty-six dogs with histologically confirmed hemangiosarcoma of various locations other than skin were used in a prospective study to determine the efficacy of adjuvant doxorubicin (30 mg/m2 IV q 3 weeks for 5 treatments) 10 to 14 days after the tumor was partially or completely excised. Analysis of the data included information on variables that were hypothesized to influence response to therapy, disease-free interval (DFI), or survival time (ST). Other information collected included age, gender, breed, weight, prior therapy, type of surgery, location of the primary tumor, presence of metastases, number of doses of doxorubicin, response to doxorubicin therapy (complete or partial response), and the following histological criteria: overall differentiation, nuclear pleomorphism, percent necrosis, mitotic score, total histological score, and grade. Surgery outcome (complete versus incomplete surgical excision) markedly influenced survival times (P < .001). Twenty percent of the dogs rendered free of disease were alive at 1 year, whereas none of the dogs that had residual tumor after surgery were alive at 1 year. Most of the histological criteria (nuclear pleomorphism, mitotic score, grade, overall differentiation) had marked (P < .05), or close to marked, independent associations with ST for dogs that had complete tumor removal. Results from analysis of DFI were generally similar to those of ST in dogs with complete excision of the tumor. Twenty-seven of the 46 dogs (58.7%) had all clinical evidence of tumour successfully removed. Logistic regression analysis of surgical outcome (ability to remove all visible tumor) suggested that age of the subject was the only factor markedly influencing surgical outcome (P = .017). As age increased, the probability of success increased. Those dogs that had previous treatment for their hemangiosarcoma tended (P = .08) to have a shorter DFI and ST. Therefore, complete removal of all evidence of tumor followed by 5 doses of doxorubicin may be an effective treatment for dogs with hemangiosarcoma. Dogs that had all tumor successfully removed had a mean and median ST of 267 and 172 days, respectively. Dogs with incomplete tumor removal had a mean and median ST of 172 and 60 days, respectively. Similarly, prognostic variables such as the ability to completely excise all evidence of tumor, histological criteria, and age of the patient are potentially important prognostic variables for predicting outcome.
46只组织学确诊为皮肤以外不同部位血管肉瘤的犬用于一项前瞻性研究，以确定在肿瘤部分或完全切除后10至14天给予阿霉素辅助治疗（30mg/m²静脉注射，每3周1次，共5次）的疗效。数据分析包括假设会影响治疗反应、无病生存期（DFI）或生存时间（ST）的变量信息。收集的其他信息包括年龄、性别、品种、体重、既往治疗、手术类型、原发肿瘤位置、转移情况、阿霉素剂量、对阿霉素治疗的反应（完全或部分反应）以及以下组织学标准：总体分化、核多形性、坏死百分比、有丝分裂评分、总组织学评分和分级。手术结果（完全与不完全手术切除）对生存时间有显著影响（P <.001）。20%无疾病的犬在1年时存活，而术后有残留肿瘤的犬在1年时均无存活。对于肿瘤完全切除的犬，大多数组织学标准（核多形性、有丝分裂评分、分级、总体分化）与ST有显著（P <.05）或接近显著的独立关联。肿瘤完全切除的犬的DFI分析结果与ST结果总体相似。46只犬中有27只（58.7%）所有肿瘤临床证据均被成功切除。手术结果（切除所有可见肿瘤的能力）的逻辑回归分析表明，受试动物的年龄是显著影响手术结果的唯一因素（P =.017）。随着年龄增加，成功的概率增加。那些曾接受血管肉瘤治疗的犬的DFI和ST往往较短（P =.08）。因此，完全切除所有肿瘤证据后给予5剂阿霉素可能是治疗犬血管肉瘤的有效方法。所有肿瘤均被成功切除的犬的平均和中位ST分别为267天和172天。肿瘤切除不完全的犬的平均和中位ST分别为172天和60天。同样，诸如完全切除所有肿瘤证据的能力、组织学标准和患者年龄等预后变量可能是预测结果的重要预后变量。
